Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory protein profile during systemic high dose interleukin-2 administration.

Leonardo Rossi1, Brian M Martin, Glen L Hortin

  • 1Department of Human Morphology and Applied Biology, University of Pisa, Pisa, Italy.

Proteomics
|December 13, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolution of PML after Treatment with Virus-Specific T Cells and HCT.

The New England journal of medicine·2026
Same author

Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia.

Cytotherapy·2026
Same author

Intra-apheresis CD34+ cell count: A dynamic approach to predicting peripheral blood stem cell collection yield.

Transfusion·2026
Same author

Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy.

JCO precision oncology·2025
Same author

Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer.

Journal for immunotherapy of cancer·2025
Same author

Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.

The Lancet. Haematology·2025

Systemic interleukin-2 (IL-2) therapy alters protein expression in renal cell carcinoma patients. Novel changes in acute-phase reactants and HDL metabolites were identified using advanced proteomic techniques.

Area of Science:

  • Biochemistry
  • Immunology
  • Proteomics

Background:

  • Systemic interleukin-2 (IL-2) administration causes complex downstream effects.
  • Previous protein array analysis revealed alterations in soluble factors during IL-2 therapy for renal cell carcinoma (RCC).
  • Methodological limitations hindered a comprehensive understanding of these systemic effects.

Purpose of the Study:

  • To expand proteomic analysis of serum from RCC patients undergoing IL-2 therapy.
  • To identify novel IL-2-specific protein expression changes beyond cytokine/chemokine profiles.
  • To compare SELDI-TOF-MS and nephelometry for analyzing systemic responses to biological response modifiers.

Main Methods:

  • Serum samples from RCC patients before and during high-dose IL-2 therapy were analyzed.

Related Experiment Videos

  • Expanded analysis included Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS) and nephelometry.
  • SELDI immunoaffinity capture and quantitative protein analysis were employed.

    • Main Results:

    • Cytokines/chemokines detected by protein arrays were below SELDI detection limits.
    • Significant IL-2-specific changes identified in acute-phase reactants and high-density lipoprotein (HDL) metabolites.
    • Serum amyloid protein A (SAA) and C-reactive protein were consistently upregulated post-IL-2; other proteins downregulated.
    • SELDI immunoaffinity capture revealed previously undetectable SAA isoforms.
    • A linear correlation was observed between SELDI peak area and nephelometry protein concentration.

    Conclusions:

    • Combined proteomic platforms provide distinct yet complementary insights into systemic IL-2 response.
    • Novel biomarkers, including SAA and CRP, are modulated by IL-2 therapy in RCC.
    • Advanced proteomic techniques are crucial for dissecting the complexity of biological response modifier effects.